DUBLIN--(BUSINESS WIRE)--Aug 21, 2018--The "Global Healthcare Licensing - Non-Listed on Stock Exchanges Trends: Biotech (Privately-owned Companies) Mid-Year Review" report has been added to ResearchAndMarkets.com's offering.

This mid-year review report brings at one place all licensing deals and negotiations that took place between the privately-owned biotech companies of Japan, US and Europe during January 1, 2018 to June 30, 2018.

Further, the licensing deals and negotiations that took place between the privately-owned biotech companies of other select regions and Japan, US and Europe during this period are also studied and included here.

Also, the licensing deals and negotiations that took place within the privately-owned biotech companies of Japan, US and Europe as well as within the privately-owned biotech companies of countries/regions other than Japan, US and Europe are studied and included here.

Moreover, all this collected data is comprehensively analyzed to understand the licensing trends and directions among the privately-owned companies during this time period.

Key Features

6 months' Japan-US-Europe licensing transactions of privately-owned biotech companies at one place 6 months' other select regions licensing transactions of privately-owned biotech companies at one place Curated categorizations of licensing details 8+ variables reflecting different forms of transactions done Canada/Australia/NZ licensing trends of privately-owned biotech companies with Japan-US-Europe covered Emerging markets licensing trends of privately-owned biotech companies with Japan-US-Europe covered Licensing trends of privately-owned biotech companies within Japan, US, Europe; and also within other select regions covered Licensing trends and directions of privately-owned biotech companies summarized

Key Analysis Provided

Total number of licensing deals of privately-owned biotech companies signed Total number of privately-owned biotech companies involved in licensing deals Most licensing deals signed by which country's privately-owned biotech companies Number of inbound and outbound licensing deals of privately-owned biotech companies Most licensing deals signed by which medicine groups Licensing payment arrangements most followed in the global licensing deals of privately-owned biotech companies Number of domestic and worldwide licensing for privately-owned biotech companies Number of R&D and commercialization licensing for privately-owned biotech companies Number of licensing deals discontinued for privately-owned biotech companies

For more information about this report visit https://www.researchandmarkets.com/research/t5cwzr/2018_global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180821005460/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Biotechnology,Healthcare Services

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 08/21/2018 10:46 AM/DISC: 08/21/2018 10:46 AM

http://www.businesswire.com/news/home/20180821005460/en